CorMedix Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$129M
↑+312.1% +$97Mvs FY2024 (Q4)
Gross Profit
$116M
↑+286.1% +$86Mvs FY2024 (Q4)
Operating Income
$59M
↑+108.5% +$31Mvs FY2024 (Q4)
Net Income
$14M
↓-50.5% -$14Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $129M | $31M |
| COGS | $12M | $1M |
| Gross Profit | $116M | $30M |
| R&D | $9M | $2M |
| SG&A | $0 | $0 |
| D&A | $294K | $82K |
| Other OpEx | $48M | $0 |
| Operating Income | $59M | $28M |
| Interest Exp. | $3M | $10K |
| Other Non-Op | $0 | $0 |
| Pretax Income | $56M | $28M |
| Tax | $42M | $0 |
| Net Income | $14M | $28M |
QuarterCharts · SEC EDGAR data · CRMD · Comparing FY2025 (Q4) vs FY2024 (Q4)